Press release
Stargardt Disease Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024
Discover the latest drugs and treatment options in the Stargardt Disease Pipeline. Dive into DelveInsight's comprehensive report today! @ Stargardt Disease Pipeline Outlook [https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Stargardt Disease Pipeline Report
* In August 2024:- Belite Bio Inc.- A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Tinlarebant in Japanese Subjects With Stargardt Disease and a Phase 2/3 Randomized, Double-masked, and Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Tinlarebant in Subjects With Stargardt Disease.
* DelveInsight's Stargardt Disease pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Stargardt Disease treatment.
* The leading Stargardt Disease Companies such as Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, Splice Bio, and others.
* Promising Stargardt Disease Therapies such as OCU410ST, Tinlarebant, ALK-001, ACDN-01, avacincaptad pegol, and others.
Stay ahead with the most recent pipeline outlook for Stargardt Disease. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Stargardt Disease Treatment Drugs [https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Stargardt Disease Emerging Drugs Profile
* Tinlarebant: Belite Bio
Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in STGD1 and also contribute to disease progression in GA, or advanced Dry AMD. Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, Tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease designation in the US, and Orphan Drug Designation in the U.S., Europe, and Japan for the treatment of STGD1. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Stargardt disease.
* KIO-301: Kiora Pharmaceuticals
KIO-301 is a molecular photoswitch designed to confer light-sensing capabilities to Retinal Ganglion Cells (RGCs). It targets patients with inherited retinal diseases where mutations lead to photoreceptor death, causing vision loss. Unlike healthy eyes where photoreceptors perform light detection, KIO-301 selectively enters RGCs downstream of degenerated photoreceptors. Inside RGCs, it interacts with voltage-gated ion channels. When exposed to light, KIO-301 changes shape, altering current flow and activating neurons to signal the brain. Removal of light causes KIO-301 to revert to its original shape, halting signaling. Essentially, KIO-301 acts as a light switch within the eye, restoring light sensitivity in patients with retinal degeneration. Currently, the drug is in Phase II stage of its clinical trial for the treatment of stargardt disease.
* OCU410: Ocugen
OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA (RAR Related Orphan Receptor A) gene. The RORA protein plays an important role in lipid metabolism, reducing lipofuscin deposits and oxidative stress, and demonstrates an anti-inflammatory role in-vitro and in-vivo (animal model) studies. These results demonstrate the ability for OCU410 to target multiple pathways linked with dAMD pathophysiology. Ocugen is developing AAV-RORA as a one-time gene therapy for the treatment of GA. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of stargardt disease.
Explore groundbreaking therapies and clinical trials in the Stargardt Disease Pipeline. Access DelveInsight's detailed report now! @ New Stargardt Disease Drugs [https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Stargardt disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
Stargardt Disease Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Stargardt Disease Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Stargardt Disease Market Drivers and Barriers [https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Stargardt Disease Pipeline Report
* Coverage- Global
* Stargardt Disease Companies- Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, Splice Bio, and others.
* Stargardt Disease Therapies- OCU410ST, Tinlarebant, ALK-001, ACDN-01, avacincaptad pegol, and others.
* Stargardt Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Stargardt Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Stargardt Disease Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Stargardt Disease Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Stargardt Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Stargardt disease - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Tinlarebant: Belite Bio
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* KIO-301: Kiora Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* OCU410: Ocugen
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Stargardt disease Key Companies
* Stargardt disease Key Products
* Stargardt disease -Unmet Needs
* Stargardt disease -Market Drivers and Barriers
* Stargardt disease -Future Perspectives and Conclusion
* Stargardt disease Analyst Views
* Stargardt disease Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=stargardt-disease-clinical-trials-pipeline-insights-treatment-drugs-and-companies-2024]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Stargardt Disease Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024 here
News-ID: 3661656 • Views: …
More Releases from ABNewswire
BRAF + NSCLC Pipeline Landscape Report 2025: Novel Therapies, Market Outlook, an …
DelveInsight's, "BRAF-mutant Non-Small Cell Lung Cancer (BRAF + NSCLC) Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in BRAF-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about…
Fit With Ana Launches AI-Powered Healthy Living Coach to Help Women Achieve Sust …
Houston, TX - September 12, 2025 - Fit With Ana, a breakthrough AI-powered weight loss coach, is transforming how women approach weight management and healthy living. Unlike traditional diet apps or generic fitness trackers, Fit With Ana offers a personalized, interactive experience that adapts to each user's lifestyle, empowering them to lose weight faster while building habits that last a lifetime.
With a mission to make sustainable health accessible for every…
South Padre Trips Leads Island's Vacation Rental Market with AI-Driven Property …
Local tourism veteran leverages 23 years of expertise to maximize owner returns and guest satisfaction
SOUTH PADRE ISLAND, Texas - South Padre Trips has earned recognition as one of if not the best South Padre Island property management company with an industry-leading 4.9-star Google review average. The top Airbnb manager on South Padre Island Texas uses innovative AI-driven pricing strategies and comprehensive management services to maximize owner returns while delivering exceptional…
Homary Announces the Top 7 Benefits of Desks with Drawers for the Back-to-School …
Image: https://www.abnewswire.com/upload/2025/09/2c271c0677bbeb1804298f85b4033d51.jpg
Adults are not the only ones to enjoy the perks of using desks at home. Many children and school-going students also appreciate a specific workspace corner to do their studies, homework, and reading.
It helps a child with a small space to do all such activities in different ways when they go through the most crucial part of their life. A home desk with drawers [https://www.homary.com/furniture/f0/desks-40.html?utm_source=backlinks&utm_campaign=referral] is also a perfect…
More Releases for Stargardt
Stargardt Disease Market is expected to reach USD 3.5 billion by 2034
Stargardt disease, the most common form of inherited juvenile macular degeneration, is caused by mutations in the ABCA4 gene. It typically manifests in late childhood or adolescence, leading to progressive central vision loss. With an estimated prevalence of 1 in 8,000 to 10,000 individuals worldwide, Stargardt disease is classified as a rare genetic disorder but represents a significant unmet need within ophthalmology.
Download Full PDF Sample Copy of Market Report @…
Stargardt Disease Market Growth to Accelerate in Forecast Period (2024-2034) | e …
DelveInsight's "Stargardt Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Stargardt Disease, historical and forecasted epidemiology as well as the Stargardt Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover Key Insights into the Stargardt Disease Market with DelveInsight's In-Depth Report @ Stargardt Disease Market Size- https://www.delveinsight.com/sample-request/stargardt-disease-stgd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Stargardt Disease Market…
Stargardt Disease Pipeline Therapeutics, Assessment, Companies, Products, Unmet …
DelveInsight's, "Stargardt Disease Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Stargardt Disease (STGD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the…
Stargardt Disease Pipeline, Clinical Trials, Emerging Therapies, and FDA Approva …
DelveInsight's, "Stargardt Disease Pipeline Insight 2023" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Stargardt Disease pipeline landscape. It covers the Stargardt Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Stargardt Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from…
Global Juvenile Degeneration (Stargardt Disease) Market Forecast to 2025
Juvenile Degeneration (Stargardt Disease) Market report describes the thorough and collective examination of the Juvenile Degeneration (Stargardt Disease) industry during the past, present and conjecture periods. All the business verticals like driving market situation, regional Juvenile Degeneration (Stargardt Disease) nearness, and improvement openings are clarified. Top players of the Juvenile Degeneration (Stargardt Disease) industry, their business strategies, and growth opportunities are covered in this report. A report is incomplete without…
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review and Research …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2017” to its report offerings. The report provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action…
